



MARYLAND MEDICAID PHARMACY PROGRAM

No. 146
July 8, 2014

ADVISORY

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Department of Health and Mental Hygiene's (DHMH) Maryland Medicaid Pharmacy Program (MMPP) has developed the Maryland Medicaid Pharmacy Program Advisory. To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations. It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via DHMH, please contact the MMPP representative at 410-767-1455.

Changes in the Generic vs. Brand Status on Maryland's Preferred Drug List

The Maryland Medicaid Pharmacy Program (MMPP) wants to alert you that effective Monday, July 21, 2014 **brands Cymbalta® (duloxetine) and Tricor® (fenofibrate nanocrystals) are no longer preferred over their generic equivalents.** Claims for duloxetine and fenofibrate nanocrystals will be handled in the same manner as claims for other multisource drugs. Fee-for-service Medicaid claims for brands Cymbalta® and Tricor® will adjudicate only if there is prior authorization based on an approved Medwatch form which can be found at the following link:

<https://mmcp.dhmh.maryland.gov/pap/docs/Maryland%20Medwatch%20Form.pdf>

Please refer to our website for a complete list of the Preferred Drug List (PDL) at the following link:

<https://mmcp.dhmh.maryland.gov/pap/SitePages/druglist.aspx>

The PDL is also available at <http://www.epocrates.com/> on your desktop computer or PDA/Smartphone. Epocrates is updated weekly.